

Siemens Healthineers Receives ARPA-H Funding of up to \$31M to Advance Remote Endovascular Robotics for Acute Stroke Treatment

- **Technology has the potential to enable autonomous remote treatment of acute ischemic stroke through mechanical thrombectomy without direct human input**
- **Autonomous remote endovascular robotics¹ can help to get the right treatment faster to eligible patients**

The Advanced Research Projects Agency for Health (ARPA-H) has awarded Siemens Healthineers up to \$31.1 million over five years to accelerate the development of autonomous remote endovascular robotics¹. This technology is designed to enable robots to perform long-distance treatment of acute ischemic stroke through mechanical thrombectomy without direct human input². Siemens Healthineers will contribute \$5.4 million as a cost share over the course of the project, bringing the total combined investment in autonomous remote endovascular robotics development to as much as \$36.5 million.

Mechanical thrombectomy is a minimally invasive procedure that removes a blood clot from a blocked blood vessel in the brain to restore blood flow following an acute ischemic stroke. When performed promptly, it can significantly improve patient outcomes and reduce the risk of long-term disability. Today, the procedure is almost exclusively available in comprehensive stroke centers – which means that large parts of the population are excluded from access. In the U.S., more than half of the population lives more than an hour from a thrombectomy-capable clinic, and only an estimated 12% of 335,000 eligible stroke patients receive mechanical thrombectomy each year². Because treatment is highly time-sensitive, every delay increases the risk of long-term disability or death, driving up healthcare costs.

“Early access to the right treatment makes all the difference for stroke patients. By integrating robotics, imaging, devices, and artificial intelligence, we want to transform the way endovascular therapy is delivered, towards greater accessibility and precision across a broader range of care settings,” said Philipp Fischer, head of Advanced Therapies at Siemens Healthineers. “The ARPA-H investment is a big step in

advancing autonomous remote endovascular robotics for the benefit of patients and communities around the world.”

Under the award, Stryker is acting as a sub-awardee, further advancing the strategic partnership established by the two companies in 2025 to accelerate innovation in robotic neurovascular interventions³. Jim Marucci, president of Stryker’s Neurovascular division, said: “This funding represents an important milestone in our collaboration with Siemens Healthineers and reinforces our shared commitment to advancing neurovascular care through innovation. Together, we're developing technologies designed to help overcome barriers to treatment and bring advanced stroke care closer to more patients and communities.”

The funding is part of the ARPA-H Autonomous Interventions and Robotics (AIR) program, led by ARPA-H Program Manager Ileana Hancu, Ph.D., and in line with the Siemens Healthineers vision to enable healthcare professionals to innovate in personalized care, achieve operational excellence, and transform the system of care.

¹ Autonomous remote endovascular robotics for acute stroke treatment is under development and not commercially available. Its future availability cannot be ensured.

² <https://arpa-h.gov/explore-funding/programs/air> (accessed on July 27, 2026).

³ The Robotic neurovascular system is under development and not commercially available. Its future availability cannot be ensured.

A press picture is available here:

<https://www.siemens-healthineers.com/press/releases/robotics-arpa-h-funding>

Further information on endovascular robotics can be found here:

<https://www.siemens-healthineers.com/endovascular-robotics>

Link to Stryker Partnership announcement:

<https://www.siemens-healthineers.com/press/releases/stryker-partnership>

Media contact

Kathrin Palder

+49 173 3645319; Kathrin.Palder@siemens-healthineers.com

Visit the [Siemens Healthineers Press Center](#).

Subscribe to our [“Medtech matters” newsletter on LinkedIn](#).

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at [siemens-healthineers.com](https://www.siemens-healthineers.com).